SS
TERN

Steve Schonfeld’s Terns Pharmaceuticals TERN Stock Holding History

Steve Schonfeld’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-165,725
Closed -$8.74M – 2999
2026
Q1 		$8.74M Sell
165,725
-588,512
-78% -$24.2M 0.06% 332
2025
Q4 		$30.5M Sell
754,237
-1,137,688
-60% -$26.3M 0.14% 122
2025
Q3 		$14.2M Sell
1,891,925
-1,157,966
-38% -$7.39M 0.08% 266
2025
Q2 		$11.4M Sell
3,049,891
-794,976
-21% -$2.48M 0.08% 299
2025
Q1 		$10.6M Sell
3,844,867
-906,639
-19% -$3.7M 0.06% 300
2024
Q4 		$26.3M Buy
4,751,506
+1,461,680
+44% +$9.9M 0.15% 114
2024
Q3 		$27.4M Buy
3,289,826
+1,021,398
+45% +$8.4M 0.18% 81
2024
Q2 		$15.4M Buy
2,268,428
+1,072,634
+90% +$6.5M 0.1% 233
2024
Q1 		$7.84M Buy
1,195,794
+787,936
+193% +$5.15M 0.05% 466
2023
Q4 		$2.65M Buy
407,858
+316,450
+346% +$1.67M 0.02% 707
2023
Q3 		$460K Sell
91,408
-27,528
-23% -$175K ﹤0.01% 1226
2023
Q2 		$1.04M Buy
118,936
+3,684
+3% +$42.9K 0.01% 957
2023
Q1 		$1.36M Buy
+115,252
New +$1.1M 0.01% 822

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Steve Schonfeld's TERN Position: Q2 2026 in Review

Steve Schonfeld sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 165,725 shares — an estimated $8.74M sold.

Steve Schonfeld first reported a position in TERN in Q1 2023 and held it in 13 quarters. The position peaked at $30.5M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Steve Schonfeld reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 165,725 Terns Pharmaceuticals shares in Q2 2026, an estimated $8.74M.
  • Steve Schonfeld first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 13 quarters.
  • Steve Schonfeld's Terns Pharmaceuticals position peaked at $30.5M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.